Topical steroids are the topical forms of corticosteroids. Topical steroids are the most commonly prescribed topical medications for the treatment of rash, eczema, and dermatitis. Topical steroids have anti-inflammatory properties, and are classified based on their skin vasoconstrictive abilities. There are numerous topical steroid products. All the preparations in each class have the same anti-inflammatory properties, but essentially differ in base and price.
Side effects may occur from
long term topical steroid use. 
Weaker topical steroids are utilized for thin-
skinned and sensitive areas, especially areas under occlusion, such as the armpit, groin, buttock crease, breast folds. Weaker steroids are used on the face, eyelids, diaper area, perianal skin, and intertrigo of the groin or body folds. Moderate steroids are used for atopic dermatitis, nummular eczema, xerotic eczema, lichen sclerosis et atrophicus of the vulva, scabies (after scabiecide) and severe dermatitis. Strong steroids are used for psoriasis, lichen planus, discoid lupus, chapped feet, lichen simplex chronicus, severe poison ivy exposure, alopecia areata, nummular eczema, and severe atopic dermatitis in adults. 
tachyphylaxis, a topical steroid is often prescribed to be used on a week on, week off routine. Some recommend using the topical steroid for 3 consecutive days on, followed by 4 consecutive days off. Long-term use of topical steroids can lead to secondary infection with  fungus or bacteria (see tinea incognito), skin atrophy, telangiectasia (prominent blood vessels), skin bruising and fragility. 
The use of the
finger tip unit may be helpful in guiding how much topical steroid is required to cover different areas of the body.
Hypothalamic pituitary adrenal axis (HPA) suppression 
Diabetes mellitus 
Topical steroid addiction Allergic
contact dermatitis (see steroid allergy)
Perioral dermatitis: This is a rash that occurs around the mouth and the eye region that has been associated with topical steroids. Ocular effects: Topical steroid drops are frequently used after
eye surgery but can also raise intra-ocular pressure (IOP) and increase the risk of glaucoma, cataract, retinopathy as well as systemic adverse effects. 
Tachyphylaxis: The acute development of tolerance to the action of a drug after repeated doses. Significant tachyphylaxis can occur by day 4 of therapy. Recovery usually occurs after 3 to 4 days rest. This has led to therapies such as 3 days on, 4 days off; or one week on therapy, and one week off therapy. 
Delivery-related adverse effects Other local adverse effects: These include facial hypertrichosis, folliculitis, miliaria, genital ulcers, and granuloma gluteale infantum. Long-term use has resulted in Norwegian scabies, Kaposi's sarcoma, and other unusual dermatosis. 
Safety in Pregnancy
A 2015 meta-analysis of observational studies of pregnancies found no association between mothers' use of topical steroids and type of delivery, APGAR score, birth defects, or prematurity.
The USA system utilizes 7 classes, which are classified by their ability to constrict
capillaries and cause skin blanching. Class I is the strongest, or superpotent. Class VII is the weakest and mildest. 
Very potent: up to 600 times stronger than
The weakest class of topical steroids. Has poor lipid permeability, and can not penetrate mucous membranes well.
Most other countries, such as the
United Kingdom, Germany, the Netherlands, New Zealand, recognize only 4 classes. In the United Kingdom and New Zealand I is the strongest, while in  Continental Europe, class IV is regarded as the strongest.
Class IV (UK/NZ: class I)
Very potent (up to 600 times as potent as hydrocortisone)
Class III (UK/NZ: class II)
Potent (50-100 times as potent as hydrocortisone)
Class II (UK/NZ: class III)
Moderate (2-25 times as potent as hydrocortisone)
Class I (UK/NZ: class IV)
Hydrocortisone 0.5-2.5% (DermAid Cream/Soft Cream, DP Lotion-HC 1%, Skincalm, Lemnis Fatty Cream HC, Pimafucort Cream/Ointment)
Japan rates topical steroids from 1 to 5, with 1 being strongest.
The highlighted steroids are often used in the screening of
allergies to topical steroid and systemic steroids. When one is allergic to one group, one is allergic to all steroids in that group.
Hydrocortisone, hydrocortisone acetate, cortisone acetate, tixocortol pivalate, prednisolone, methylprednisolone, and prednisone
Triamcinolone acetonide, triamcinolone alcohol, amcinonide, budesonide, desonide, fluocinonide, fluocinolone acetonide, and halcinonide
Betamethasone, betamethasone sodium phosphate, dexamethasone, dexamethasone sodium phosphate, and fluocortolone
Hydrocortisone-17-butyrate, hydrocortisone-17-valerate, alclometasone dipropionate, betamethasone valerate, betamethasone dipropionate, prednicarbate, clobetasone-17-butyrate, Clobetasol-17 propionate, fluocortolone caproate, fluocortolone pivalate, fluprednidene acetate, and mometasone furoate
Corticosteroids were first made available for general use around 1950.
^ a b
Habif, Thomas P. (1990). Clinical dermatology: a color guide to diagnosis and therapy (2nd ed.). St. Louis: Mosby. p. 27. ISBN 0-8016-2465-7.
Coondoo, A; Phiske, M; Verma, S; Lahiri, K (2014). "Side effects of topical steroids: A long overdue revisit". Indian Dermatol Online J. 5 (4): 416-25. doi: 10.4103/2229-5178.142483. PMC . 4228634 PMID 25396122.
^ Recommendations from New Zealand Dermatological Society Incorporated on
Habif, Thomas P. (1990). Clinical dermatology: a color guide to diagnosis and therapy (2nd ed.). St. Louis: Mosby. pp. 27-30. ISBN 0-8016-2465-7.
Fisher, DA (1995). "Adverse effects of topical corticosteroid use". West. J. Med. 162 (2): 123-6. PMC . 1022645 PMID 7794369.
van der Linden MW, Penning-van Beest FJ, Nijsten T, Herings RM (2009). "Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands". Drug Saf. 32 (6): 527-37. doi: 10.2165/00002018-200932060-00008. PMID 19459719.
Lebreton, O.; Weber, M. (2011). "Complications ophtalmologiques des corticoïdes systémiques". La Revue de Médecine Interne. 32 (8): 506-512. doi: 10.1016/j.revmed.2011.01.003. PMID 21330017.
Wolverton, Stephen E. (2001). Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company. pp. 562-3. ISBN 0-7216-7728-2.
Wolverton, Stephen E. (2001). Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company. p. 563. ISBN 0-7216-7728-2.
Chi, Ching-Chi; Wang, Shu-Hui; Wojnarowska, Fenella; Kirtschig, Gudula; Davies, Emily; Bennett, Cathy (2015-10-26). "Safety of topical corticosteroids in pregnancy". Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.CD007346.pub3. ISSN 1465-1858.
Habif, Thomas P. (1990). Clinical dermatology: a color guide to diagnosis and therapy (2nd ed.). St. Louis: Mosby. p. Inside front cover. ISBN 0-8016-2465-7.
Wolverton, Stephen E. (2001). Comprehensive Dermatologic Drug Therapy. Philadelphia, PA: W.B. Saunders Company. p. 562. ISBN 0-7216-7728-2.
Rattner H (November 1955). "THE STATUS OF CORTICOSTEROID THERAPY IN DERMATOLOGY". Calif Med. 83 (5): 331-5. PMC . 1532588 PMID 13260925.